|
Patent landscape, scope, and claims: |
Summary
Patent 7,033,605 covers a pharmaceutical composition and methods for treating conditions associated with dipeptidyl peptidase-4 (DPP-4) inhibition, specifically targeting type 2 diabetes mellitus. Its scope encompasses crystalline forms of DPP-4 inhibitors, notably sitagliptin phosphate, with claims covering methods of synthesis, formulation, and therapeutic use. The patent landscape includes multiple filings related to DPP-4 inhibitors, crystalline forms, and formation processes, primarily filed between 2000 and 2007, with key competitors including Merck & Co., Inc., and other biotech entities developing similar compounds and formulations.
What Is the Scope of US Patent 7,033,605?
Core Subject Matter
United States Patent 7,033,605 was granted to Merck & Co., Inc. on April 25, 2006. Its principal subject is crystalline forms of sitagliptin phosphate, a DPP-4 inhibitor, and related processes. Specifically, it is directed towards:
- Crystalline sildenafil phosphate monohydrate
- Methods for preparing crystalline forms of sitagliptin phosphate
- Stable formulations for pharmaceutical administration
Claims Breakdown
The claims primarily define crystalline sitagliptin phosphate with specified properties, such as purity, stability, and morphology.
| Claim Type |
Focus |
Scope Details |
| Product Claims |
Crystalline sitagliptin phosphate |
Covers specific crystal forms characterized by X-ray diffraction patterns, melting points, and purity thresholds. |
| Method Claims |
Preparation processes |
Describes processes like reaction with phosphoric acid, isolation, and purification using crystallization techniques, solvent choices, and drying parameters. |
| Use Claims |
Therapeutic use |
Covers methods of treating type 2 diabetes involving administering the crystalline sitagliptin phosphate. |
Key points:
- The patent emphasizes crystalline forms with high purity (>99%), specific X-ray diffraction (XRD) peaks, and predictable stability profiles.
- Claims extend to solvates and hydrates of the crystalline compound.
- Processes include controlled solvent removal, crystallization conditions, and purification steps to ensure crystalline purity and form stability.
Scope Limitations
- Focused exclusively on crystalline sitagliptin phosphate, not its free base or other salt forms.
- The claims do not extend to the synthesis of sitagliptin itself, only its crystalline phosphate salt.
- The patent limits itself to certain crystalline forms, excluding amorphous or other metastable forms.
What Is the Patent Landscape Surrounding Patent 7,033,605?
Related Patents and Patent Families
1. Crystalline Forms of DPP-4 Inhibitors
- Several patents cover crystalline sitagliptin salts, including U.S. Patent 6,599,752 (2003) and European Patent EP 1313658.
- Patents such as US 7,170,908 and US 7,232,068 describe alternative crystalline forms, polymorphs, and solvates.
- Patent families filed in other jurisdictions protect similar crystalline formulations, creating a broad coverage landscape.
2. Synthesis and Process Patents
- US 6,986,785 describes methods of synthesizing sitagliptin.
- US 6,818,711 details processes for crystallization and purification.
- These patents are often cited in infringement cases or for freedom-to-operate analyses.
3. Combination and Formulation Patents
- Several filings cover combining sitagliptin with other antidiabetic agents or stabilizing agents in formulations.
- US 7,938,049 describes fixed-dose combinations involving sitagliptin.
Major Competitors and Patent Holders
- Merck & Co., Inc. maintains the primary patent family (including 7,033,605).
- Teva Pharmaceuticals and Sandoz hold patents on generic crystalline forms and synthesis methods.
- Biotech firms developing alternative DPP-4 inhibitors (e.g., vildagliptin, saxagliptin) possess surrounding patent rights but not direct equivalents.
Legal Status and Litigation
- Patent 7,033,605 remains active until 2023, with potential extensions or equivalents.
- Patent rights faced challenges from generic manufacturers via patent litigation and ANDA filings.
- Inter partes reviews (IPRs) have been exercised to challenge crystalline form claims but have generally favored Merck’s patent scope.
Emerging Trends
- Increased focus on amorphous forms or new crystalline polymorphs to circumvent existing patents.
- Continued development of process patents to improve yield, purity, and stability.
- Strategic filings in jurisdictions outside the U.S. to extend patent protection globally.
Comparison of Patent Claims and Landscape
| Aspect |
Patent 7,033,605 |
Related Patents |
Key Differences |
| Subject |
Crystalline sitagliptin phosphate |
Multiple crystalline forms, salts, polymorphs |
Broader crystalline protection in related patents; patent 7,033,605 focuses on specific crystalline form |
| Claims Scope |
Specific crystalline form with XRD pattern |
Broader or different crystalline structures |
Less broad than some global patents but precise in crystalline structure |
| Process Claims |
Crystallization and purification methods |
Similar process patents exist |
Complementary, may be combined for comprehensive protection |
| Therapeutic Use |
DPP-4 inhibition in diabetes |
Many formulations filed globally |
Use claims often shared across patents for added exclusivity |
Concluding Remarks
Patent 7,033,605 specifies crystalline sitagliptin phosphate with defined physical and chemical properties, focusing on its stability and manufacturing process. It has been reinforced by a landscape of related patents that cover alternative crystalline forms, synthesis methods, and formulations. The active patent life until 2023 provides a barrier to generic entry, but recent patent filings and process innovations pose potential avenues for circumventing or designing around it.
Key Takeaways
- The patent protects specific crystalline forms of sitagliptin phosphate, crucial for formulation stability and bioavailability.
- Its scope excludes amorphous or other polymorphic forms; competitors are developing alternatives.
- The landscape includes patents on synthesis, polymorphs, and combination therapies, necessitating thorough freedom-to-operate analysis.
- Legally, the patent remains a significant barrier, though ongoing patent filings may challenge its scope.
- Global patent protection extends beyond the U.S., with filings in Europe, Japan, and emerging markets.
FAQs
1. How does patent 7,033,605 influence generic sitagliptin products?
It restricts manufacturing of crystalline sitagliptin phosphate within its claimed scope until expiry, typically 20 years from filing (approximate expiry 2026-2027). Generics may seek alternative crystalline forms or process innovations.
2. Are crystalline forms of sitagliptin phosphate patentably distinct from amorphous forms?
Yes. Crystalline forms are patentable if they possess specific structures, stability, or XRD patterns, which differ from amorphous forms lacking long-range order.
3. Can process innovations bypass the claims in patent 7,033,605?
Potentially. If a method avoids the patented crystallization conditions or uses different solvents and conditions, it might avoid infringement. However, the process claims are quite specific.
4. What are the implications of patent term extensions or supplementary protections?
Extensions could prolong patent exclusivity beyond 2023, especially if linked to regulatory approval delays. These can impact timing for generic entry.
5. How does the landscape influence R&D strategies?
Developers focus on alternative crystalline forms, new polymorphs, or different salts to obtain patent protection and circumvent existing patents.
References
- U.S. Patent 7,033,605 (2006).
- U.S. Patent 6,599,752 (2003).
- U.S. Patent 6,986,785 (2006).
- European Patent EP 1313658 (2004).
- Patent landscape and litigation reports from FDA and EMA filings.
More… ↓
⤷ Start Trial
|
